CO2021005207A2 - Métodos de tratamiento - Google Patents
Métodos de tratamientoInfo
- Publication number
- CO2021005207A2 CO2021005207A2 CONC2021/0005207A CO2021005207A CO2021005207A2 CO 2021005207 A2 CO2021005207 A2 CO 2021005207A2 CO 2021005207 A CO2021005207 A CO 2021005207A CO 2021005207 A2 CO2021005207 A2 CO 2021005207A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment methods
- methods
- cancer
- compositions
- tumor antigens
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Abstract
En la presente se proporcionan métodos y composiciones para identificar antígenos tumorales de linfocitos humanos y para tratar sujetos que tienen cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737862P | 2018-09-27 | 2018-09-27 | |
PCT/US2019/053669 WO2020069452A1 (en) | 2018-09-27 | 2019-09-27 | Treatment methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021005207A2 true CO2021005207A2 (es) | 2021-07-30 |
Family
ID=69953226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0005207A CO2021005207A2 (es) | 2018-09-27 | 2021-04-22 | Métodos de tratamiento |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230041057A1 (es) |
EP (1) | EP3856207A4 (es) |
JP (1) | JP2022502433A (es) |
KR (1) | KR20210091137A (es) |
CN (1) | CN113194967A (es) |
AU (1) | AU2019351273A1 (es) |
BR (1) | BR112021005596A2 (es) |
CA (1) | CA3113259A1 (es) |
CO (1) | CO2021005207A2 (es) |
EA (1) | EA202190862A1 (es) |
IL (1) | IL281792A (es) |
MX (1) | MX2021003262A (es) |
SG (1) | SG11202102878TA (es) |
WO (1) | WO2020069452A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
JP2023504042A (ja) * | 2019-11-27 | 2023-02-01 | ミスト セラピューティクス リミテッド ライアビリティ カンパニー | 調節物質を使用した腫瘍反応性t細胞組成物の生成方法 |
CN113278731A (zh) * | 2021-05-12 | 2021-08-20 | 广西医科大学 | 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021995A2 (en) * | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
ZA200602941B (en) * | 2003-11-13 | 2007-07-25 | Genentech Inc | Screening assays and methods of tumor treatment |
CA2568344C (en) * | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
EP1910521B1 (en) * | 2005-08-05 | 2010-10-13 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Generation of allorestricted antigen specific t cells |
JP2010235611A (ja) * | 2010-05-10 | 2010-10-21 | Ortho Mcneil Pharmaceut Inc | 腫瘍の治療のための細胞治療方法 |
CN105979961B (zh) * | 2014-02-05 | 2020-12-18 | 西达-赛奈医疗中心 | 用于治疗癌症和感染性疾病的方法和组合物 |
TWI742008B (zh) * | 2015-11-02 | 2021-10-11 | 美商健生生物科技公司 | 使用特異性結合cd38之抗體免疫調節及治療固態腫瘤 |
-
2019
- 2019-09-27 CN CN201980075999.7A patent/CN113194967A/zh active Pending
- 2019-09-27 US US17/280,498 patent/US20230041057A1/en active Pending
- 2019-09-27 MX MX2021003262A patent/MX2021003262A/es unknown
- 2019-09-27 CA CA3113259A patent/CA3113259A1/en active Pending
- 2019-09-27 WO PCT/US2019/053669 patent/WO2020069452A1/en unknown
- 2019-09-27 BR BR112021005596-7A patent/BR112021005596A2/pt not_active Application Discontinuation
- 2019-09-27 JP JP2021517298A patent/JP2022502433A/ja active Pending
- 2019-09-27 SG SG11202102878TA patent/SG11202102878TA/en unknown
- 2019-09-27 EP EP19864650.7A patent/EP3856207A4/en active Pending
- 2019-09-27 EA EA202190862A patent/EA202190862A1/ru unknown
- 2019-09-27 AU AU2019351273A patent/AU2019351273A1/en active Pending
- 2019-09-27 KR KR1020217012709A patent/KR20210091137A/ko unknown
-
2021
- 2021-03-24 IL IL281792A patent/IL281792A/en unknown
- 2021-04-22 CO CONC2021/0005207A patent/CO2021005207A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021005596A2 (pt) | 2021-06-29 |
US20230041057A1 (en) | 2023-02-09 |
EA202190862A1 (ru) | 2021-07-07 |
MX2021003262A (es) | 2021-07-15 |
WO2020069452A1 (en) | 2020-04-02 |
CA3113259A1 (en) | 2020-04-02 |
EP3856207A1 (en) | 2021-08-04 |
IL281792A (en) | 2021-05-31 |
AU2019351273A1 (en) | 2021-05-20 |
JP2022502433A (ja) | 2022-01-11 |
EP3856207A4 (en) | 2022-11-16 |
CN113194967A (zh) | 2021-07-30 |
KR20210091137A (ko) | 2021-07-21 |
SG11202102878TA (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011148A (es) | Metodos de tratamiento. | |
CO2021005207A2 (es) | Métodos de tratamiento | |
BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
GT201700286A (es) | Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38 | |
PE20210288A1 (es) | Anti-cd25 para el agotamiento de celulas tumorales especificas | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
BR112018013731A2 (pt) | combinações anti-egfr para o tratamento de tumores | |
EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
BR112016022345A2 (pt) | terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40 | |
BR112016005303A2 (pt) | anticorpos anti-b7-h1 para tratamento de tumores | |
EA201792642A1 (ru) | Способы диагностики для т-клеточной терапии | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
MD3302471T2 (ro) | Compuși de alchenă tetrasubstituiți și utilizarea acestora | |
BR112018013733A2 (pt) | combinações anti-cd20 para o tratamento de tumores a | |
CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
BR112018069023A2 (pt) | métodos de tratamento de doenças colestáticas | |
CO2021005234A2 (es) | Métodos de tratamiento | |
CY1124123T1 (el) | Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου | |
WO2017040666A3 (en) | Combination therapy for treatment of disease | |
BR112021022784A2 (pt) | Composições e métodos para tratamento do câncer | |
BR112017025533A2 (pt) | método para tratar câncer em um paciente humano | |
CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al |